TNF blocking drugs persist in infants after exposure in-utero

Reuters Health Information: TNF blocking drugs persist in infants after exposure in-utero

TNF blocking drugs persist in infants after exposure in-utero

Last Updated: 2016-05-13

By Anne Harding

NEW YORK (Reuters Health) - Babies born to mothers who took anti-tumor necrosis factor (anti-TNF) agents during pregnancy have detectable drug in their bodies up to 12 months of age, new findings show.

These infants should therefore not receive live vaccines during their first year of life, Dr. Mette Julsgaard of Aarhus University Hospital in Denmark and her colleagues concluded in a report online April 7 in Gastroenterology.

Many women with inflammatory bowel disease (IBD) require treatment with anti-TNF drugs during pregnancy, Dr. Julsgaard and her team note. They add that while studies have so far not linked in utero exposure to adverse neonatal outcomes, there is little data on how infants clear the drug and whether exposure may affect childhood development.

To investigate, the researchers looked at 80 mother-baby pairs from Denmark, Australia and New Zealand. Thirty-six of the mothers received adalimumab during pregnancy, 44 infliximab, and 39 also received thiopurines.

Median duration of anti-TNF treatment was 2.5 years. Women on adalimumab received their last pregnancy dose at median gestational week (GW) 35, while the last dose of infliximab was given at median GW 30. Thirty-eight women had a disease relapse while pregnant, while 42 remained in remission.

Cord blood concentrations of anti-TNF agents were higher than maternal concentrations, with a median ratio of infant to maternal concentration at birth of 1.21 for adalimumab and 1.97 for infliximab. Both maternal and cord blood concentrations were inversely correlated with duration since last exposure.

Eight of the babies exposed to adalimumab (22%) had no detectable level of the drug in their cord blood, while infliximab was detected at birth in all of the exposed infants. Mean time to clearance was 4 months with adalimumab and 7.3 months with infliximab. One infant had detectable levels of infliximab at 12 months, which were cleared by age 15 months.

Four infants developed bacterial infections during their first year, while 16 had viral infections, all of which had benign courses. The relative risk of any infection was 2.7 for infants born to mothers who received both an anti-TNF agent and thiopurine, compared to those on anti-TNF monotherapy.

"It is reassuring that all infant infections had a benign course. Still, combination therapy in pregnant women should be carefully counterbalanced between risk of disease activity in pregnancy (if thiopurine is discontinued) and thereby increased risk of adverse pregnancy outcome such as preterm birth and small for gestational age, and an increased risk of infection in the offspring if combination therapy is continued," Dr. Julsgaard told Reuters Health via e-mail. "Therefore pregnant women on combination therapy should receive thorough counseling."

The risk of live vaccines for infants born to mothers on anti-TNF agents probably outweighs the benefit, the researcher added. "However at one year of age, infants exposed to anti-TNF-alpha in utero can receive live vaccines such as measles, mumps and rubella and varicella in order to protect the infant from potentially severe illness."

SOURCE: http://bit.ly/23Oqq5Y Gastroenterology, online April 8, 2016.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.